Equillium Announces Poster Presentations at the 7th International AHR Conference

New preclinical data further characterize EQ504’s effects on epithelial barrier repair and immune regulationLA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. NASDAQ:EQ, a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, tod…